TP53 RB1 and PTEN alterations affect prognosis and ARPI response in metastatic hormone-sensitive prostate cancer, potential for treatment personalization based on both genomic testing and clinical ...

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

The integration of liquid biopsies in the clinical management of metastatic prostate cancer offers a minimally invasive method for monitoring disease progression and treatment response in real-time.

Zachary Klaassen interviews Neal Shore about a presentation on health-related quality of life outcomes from the PSMAfore trial. Dr. Shore explains that while the VISION trial established Pluvicto's™ ...

ASCO 2025, Non–muscle-Invasive Bladder Cancer (NMIBC), Intravesical Sacituzumab Tirumotecan, Intermediate-Risk Non–muscle-Invasive Bladder Cancer, TroFuse-027 Study, Trophoblast cell-surface antigen 2 ...

Mario Fernández, MD, Melanie Pepin, MS, CGC, and Kristen Watts The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, was host to the Breakout Session: Tracking and Tackling an ...

Prostatitis - Read the latest Prostatitis research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

PSMA and Beyond 2025 PSMAfore trial, SPLASH trial, ECLIPSE trial, PSMA radioligand therapy, PSMAfore compared to SPLASH, SPLASH LuPSMA arm, PSMAfore LuPSMA arm, ProstACT GLOBAL.

(UroToday.com) The 2025 European Association of Urology (EAU) Annual Congress held in Madrid, Spain between March 21 st and 24 th 2025, was host to a thematic session on intravesical therapy for ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured an alpha and other radionuclides session and a presentation by Dr. Alfred Morgenstern discussing 212 Pb-PSMA versus 225 Ac-PSMA. Dr.

ASCO 2025 fully automated PSMA PET quantification, overall survival in patients undergoing 177Lu PSMA therapy, PSMA SUVmean, metastatic castrate resistant prostate cancer (mCRPC).